Recruiting
Multidisciplinary Approach to Fatigue
Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour
ClinicalTrials.gov IDNCT05502224
PhaseNA
Enrollment50
SponsorJules Bordet Institute
Age18 Years
SexALL
Conditions studied
Breast Cancer, Germ Cell Tumor
About this study
Prospective longitudinal, single-center, non-randomized study for the implementation of an integrated multidisciplinary fatigue follow-up for young patients with breast cancer or germ cell tumour
Interventions
- Other: Ergospirometry — Maximum aerobic capacity (VO2 max), Maximum load, Ventilatory threshold and the patient's RQ
Primary outcomes
- Evaluate the feasibility of the specific fatigue management program (Through study completion, an average of 4 years)
Eligibility information
Inclusion Criteria:
* Age between 18 and 39 years at the time of signing the informed consent
* Patient who speaks and understands French
* Signed study informed consent form obtained prior to any study related procedures
* At minimum, a moderate (\>3) fatigue level according to the Standard Rating Scale (NRS) 1 month after completion of acute treatment; as measured at the Survivorship of the standard program
* Patient with either: curative breast cancer (AJCC stage I-II-III) or a germ cell tumor
Exclusion Criteria:
* Refusal to participate in the study
* Patient having chosen to participate in another psychosocial intervention study for the duration of the study.
* Patients with AJCC stage IV breast cancer
Study locations
- Institut Jules Bordet, Brussels, 1070 Belgium
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-28.